Glaukos Corporation $GKOS Shares Bought by Blair William & Co. IL

Blair William & Co. IL raised its holdings in shares of Glaukos Corporation (NYSE:GKOS) by 1.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 47,250 shares of the medical instruments supplier’s stock after acquiring an additional 518 shares during the quarter. Blair William & Co. IL owned approximately 0.08% of Glaukos worth $4,880,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. US Bancorp DE lifted its stake in shares of Glaukos by 12.6% during the second quarter. US Bancorp DE now owns 6,752 shares of the medical instruments supplier’s stock valued at $697,000 after buying an additional 758 shares during the period. Maryland State Retirement & Pension System raised its holdings in Glaukos by 4.7% in the 2nd quarter. Maryland State Retirement & Pension System now owns 16,793 shares of the medical instruments supplier’s stock valued at $1,735,000 after acquiring an additional 751 shares during the last quarter. Louisiana State Employees Retirement System lifted its stake in shares of Glaukos by 2.7% during the 2nd quarter. Louisiana State Employees Retirement System now owns 26,700 shares of the medical instruments supplier’s stock worth $2,758,000 after purchasing an additional 700 shares during the period. KLP Kapitalforvaltning AS boosted its holdings in shares of Glaukos by 7.3% during the second quarter. KLP Kapitalforvaltning AS now owns 11,700 shares of the medical instruments supplier’s stock worth $1,208,000 after purchasing an additional 800 shares during the last quarter. Finally, Truist Financial Corp boosted its holdings in shares of Glaukos by 138.9% during the second quarter. Truist Financial Corp now owns 7,296 shares of the medical instruments supplier’s stock worth $754,000 after purchasing an additional 4,242 shares during the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Glaukos Stock Down 5.1%

GKOS stock opened at $82.55 on Monday. The stock has a market cap of $4.73 billion, a PE ratio of -50.03 and a beta of 0.76. The firm’s 50-day simple moving average is $87.95 and its 200 day simple moving average is $92.61. Glaukos Corporation has a fifty-two week low of $77.10 and a fifty-two week high of $163.71. The company has a quick ratio of 4.69, a current ratio of 5.51 and a debt-to-equity ratio of 0.09.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.02. The business had revenue of $124.12 million for the quarter, compared to analysts’ expectations of $115.49 million. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The company’s revenue was up 29.7% on a year-over-year basis. During the same period in the previous year, the business earned ($0.52) earnings per share. Glaukos has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Glaukos Corporation will post -1.08 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on GKOS shares. UBS Group increased their target price on Glaukos from $125.00 to $134.00 and gave the stock a “buy” rating in a research report on Thursday, July 31st. Truist Financial dropped their price target on Glaukos from $126.00 to $120.00 and set a “buy” rating for the company in a research note on Monday, September 22nd. Mizuho set a $130.00 price objective on Glaukos in a report on Thursday, July 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Glaukos in a report on Wednesday, October 8th. Finally, Zacks Research downgraded shares of Glaukos from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Glaukos presently has an average rating of “Moderate Buy” and an average target price of $118.00.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.